ArticleFrontiers in cellular and infection microbiology2026
Identification of efflux inhibitors through a drug repurposing strategy in
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methods: Using the DrugBank database, we screened predicted membrane transport proteins in Results: A total of 245 predicted membrane transport proteins were screened, 51 of which showed homology to known drug targets and were associated with 777 drugs. A subset of 59 drugs was selected for screening. The drug miltefosine showed the lowest minimum inhibitory concentration (MIC; 2 mg/L), while amlodipine and procainamide demonstrated an adjuvant effect by decreasing the MIC of fluconazole by at least four-fold. Fluorometric assays revealed amlodipine, fluvoxamine and fluoxetine as potential efflux inhibitors in Discussion: These findings highlight the potential of these drugs to contribute to the research and development of new therapeutic alternatives aimed at combating antifungal resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.